EUROPEAN ACADEMIC RESEARCH
Vol. XII, Issue 12/ March 2025

Impact Factor: 3.4546 (UIF)
DRJI Value: 5.9 (B+)

ISSN 2286-4822
www.euacademic.org

A Review of the Mechanics, Prevalence, Affecting Variables, and Different Strategies for Antibiotic Resistance

HAIDER QASSIM RAHEEM
DNA Research center, University of Babylon
Al-Karamah Street - 51001, Babylon state, Iraq
haiderbio412@gmail.com
haider.qassim@uobabylon.edu.iq
https://orcid.org/0000-0001-8250-7777

Abstract

Since their discovery in the early 1900s, antibiotics have transformed medicine and saved countless lives. However, the worrying increase in antibiotic resistance has eclipsed the history of antibiotics. The unrelenting adaptability of microbes is the cause of this global disaster caused by the overuse and abuse of antibiotics. The history of antibiotics and the subsequent development of antibiotic resistance are examined in this article. It explores the methods bacteria use to become resistant, emphasizing the grave repercussions of medication resistance, such as worse patient care, higher death rates, and rising medical expenses. The article describes the most recent tactics for combating drug-resistant microbes, including cutting-edge methods like phage treatment,CRISPR-Cas9 technology,and the investigation of natural chemicals.Additionally, it looks at how antibiotic resistance significantly affects medication development,making the search for new antibiotics financially difficult.The constraints and difficulties in creating innovative Antibiotics and regulatory roadblocks that impede advancement in this crucial area are covered. There are suggestions made for altering the regulatory procedure to speed up the creation of antibiotics. Major pharmaceutical companies' departure from antibiotic research is discussed, along with possible ways to pique their interest again. The article highlights global alliances and collaborations while outlining efforts to overcome financial obstacles and encourage the development of antibiotics

Keywords: antibiotic resistance; drug designing; horizontalgene transfer; public and agricultural health.

INTRODUCTION

The development of antibiotic resistance Dr. Tedros Adhanom Ghebreyesus, the director-general of the World Health Organization (WHO), has underscored that the worldwide increase in antibiotic resistance jeopardizes a century of healthcare advancements and threatens the attainment of sustainable development objectives. Current forecasts suggest that, over the next 25 years, almost all bacterial strains will develop resistance to the majority of antibiotics used in clinical settings. Experts project that antimicrobial resistance may lead to around 10 million fatalities each year by the middle of the century, a significant rise from the present annual death toll of over 700,000 [1].In response to escalating concerns over antibiotic resistance, the World Health Organization (WHO) assembled a list in 2017, categorizing bacterial species based on their resistance patterns. This enumeration comprises *Staphylococcus aureus,*

Helicobacter pylori, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterococcus faecium, Salmonella species, Campylobacter species, and Neisseria gonorrhoeae. These bacterial species have considerable resistance to many types of antibiotics, making them less susceptible to standard antibiotic therapies [2].

Antibiotic Resistance Mechanisms

Bacteria employ three main mechanisms to mitigate the effects of antibiotics[3] . The following mechanisms are delineated:

1.Bacteria Inhibit the Accumulation of Antibiotics Within their Cells.

1.1 Enhancing the Efflux of Antibiotics from Bacterial Cells

The efflux pumps, found in the cytoplasmic membrane of bacteria, show a crucial part in preserving solute equilibrium within bacterial cells.These pumps pay to resistance to antibiotic by expelling drugs from cells prior to their reaching intended targets [4] (Figure 1). Efflux systems confer resistance to entirely classes of antibiotics except for polymyxin[5].Enhancing our comprehension of the machines that regulate efflux systems may lead to novel stratagems for addressing antibiotic resistance.



FIGURE (1) Mechanism of antibiotic resistance by increasing antibiotic exit from the bacterial cell.

1.2 Restricting Drug Influx into Bacterial Cells

Porin channels are current in the gram-negative bacteria outer membrane [6]. These canals act as selective porters, permitting lone specific antibiotics, including ß-lactams and quinolones, to penetrate the bacterial cell. A decrease in bacterial porin quantity can hinder antibiotic entry, principal to improved resistance to these medications [7] .



FIGURE (2) Mechanism of antibiotic resistance by decreasing antibiotic entry into the bacterial cell.

2. Bacteria Alter the Target Molecule of Antibiotics

Antibiotics are engineered to target molecules within bacterial cells specifically. Minor alterations to target molecules can hinder the effective binding of antibiotics, resulting in the emergence of antibiotic resistance [8].

2.1 Modifications in Penicillin-Binding Proteins (PBPs)

Penicillin-binding proteins (PBPs) function as transpeptidase enzymes that are crucial for the cross-linking of peptidoglycan precursors in the synthesis of bacterial cell walls. ß-lactam antibiotics primarily target these enzymes, and any structural or functional changes in PBPs may result in bacterial resistance to this class of drugs[9]. Figure 3



FIGURE (3) Mechanism of antibiotic resistance by alteration in penicillin-binding protein.

2.2 Alterations to the Ribosomal 30S or 50S Subunits

Bacteria can acquire resistance to antibiotics that inhibit protein synthesis through modifications of their ribosomal 30S or 50S [10] (Figure 4).Modifications are often linked to antibiotic resistance, encompassing aminoglycosides, tetracycline, macrolides, chloramphenicol, lincosamides, and streptogramins [11].



FIGURE (4) Mechanism of antibiotic resistance by alteration in 50 s ribosomal subunit.

2.3 Modifications to DNA Gyrase and Topoisomerase Enzymes

The process of DNA replication relies on the function of two essential enzymes: DNA gyrase and topoisomerase [12]. Quinolone antibiotics specifically inhibit these enzymes, and structural alterations in DNA gyrase or topoisomerase may result in bacterial resistance to quinolones [13] (Figure 5).



FIGURE (5) Mechanism of antibiotic resistance by alteration in DNA gyrase and topoisomerase IV.

2.4 Modifications in D-alanyl-D-alanine

Peptidoglycan precursors consist of a dipeptide residue, D-alanyl-D-alanine, which is crucial for the synthesis of bacterial cell walls [14] Modifications to this residue may main to bacterial resistance against antibiotics [15].

2.5 Changes in RNA Polymerase Contributing to Rifampicin Resistance

Rifampicin, an antibiotic utilized for bacterial infections, functions by inhibiting RNA synthesis. This mechanism involves binding to the beta subunit of the DNA-dependent RNA polymerase enzyme, thereby inhibiting the transcription of DNA into RNA, which ultimately disrupts bacterial growth and induces cell death [16].

Bacteria can develop resistance to rifampicin via mutations in the rpoB gene, which is responsible for encoding the beta subunit of RNA polymerase. Mutations modify the enzyme's structure, leading to a decreased binding capacity of the antibiotic and consequently reducing its efficacy [17].

Mutations in the RNA polymerase enzyme can influence its binding affinity for rifampicin, consequently diminishing the antibiotic's efficacy in inhibiting RNA synthesis.

Modifications in RNA polymerase associated with rifampicin resistance can result in various outcomes. The disruption of peptidoglycan precursor levels significantly impacts bacterial cell wall synthesis. Disruptions may compromise the integrity and stability of the cell wall, potentially affecting bacterial susceptibility to other antibiotics, including ß-lactams [17].

Rifampicin resistance can develop via various mechanisms. Mutations in RNA polymerase represent one mechanism of resistance; however, additional pathways include the horizontal transfer of resistance genes and the overexpression of efflux pumps, which facilitate the active removal of rifampicin from bacterial cells [16]

2.6 Mechanisms of Ribosomal Protection

Tetracycline antibiotics inhibit bacterial protein synthesis by targeting the ribosomal 30S subunit. Bacteria can develop ribosomal protection mechanisms that allow them to counteract the effects of these antibiotics [6].

3. Bacteria Enzymes Inactivate Antibiotics

Bacteria employ diverse enzymatic mechanisms to counteract antibiotics. Three key enzymes are particularly significant:

3.1 Chloramphenicol acetyltransferase enzymes

Chloramphenicol-acetyltransferase enzymes are essential in antibiotic resistance, as they modify chloramphenicol via the acetylation of its hydroxyl group.This structural modification inhibits the antibiotic's binding to its ribosomal target, thereby neutralizing its antibacterial efficacy.Bacteria that produce chloramp henicol-acetyltransferase enzymes demonstrate resistance to chloramphenicol, thus making these antibiotics ineffective [18].

3.2 Beta-Lactamase Enzymes

Beta-lactamase enzymes, produced by specific bacterial strains, hydrolyze ß-lactam antibiotics by cleaving the ester and amide bonds in their chemical structure. This process allows bacteria to acquire resistance, thereby making ß-lactam antibiotics ineffective against these strains [11].



FIGURE (6) Mechanism of antibiotic resistance by inactivation of the antibiotic.

3.3 Aminoglycoside-Modifying Enzymes

Aminoglycoside-modifying enzymes (AMEs) are crucial in the emergence of antibiotic resistance, as they inhibit the binding of aminoglycoside antibiotics to their ribosomal targets [19].These enzymes are commonly found in various bacterial strains, such as *E. faecalis, S. aureus, and S. pneumoniae*. AMEs not only inhibit antibiotic attachment but also provide resistance to aminoglycosides and fluoroquinolones [6] . The prevalence of AMEs in bacterial pathogens significantly undermines the efficacy of antibiotics, thereby complicating the management of bacterial infections.

4. The Dissemination of Antibiotic Resistance in Bacteria

Antibiotic resistance arises when a microorganism is capable of surviving or proliferating in antibiotic concentrations that would normally inhibit or eliminate other organisms of the same species[20].In clinical practice,the terms "susceptible" and "resistant" describe the probability of effective antibiotic treatment[21]. Resistance is more likely to occur when the necessary antibiotic concentration to inhibit or eliminate bacteria is not attained in the patient [22].

Microorganisms can exhibit intrinsic resistance or develop it after exposure to antibiotics[23]. Resistance may arise from genetic mutations or the acquisition of

resistance genes [24].These genes, frequently located on plasmids mobile genetic elements can disseminate via various mechanisms:

Conjugation refers to the transfer of plasmids between bacterial cells, Transformation refers to the uptake of naked DNA by bacteria [25] .

Transduction refers to the transfer of genetic material through bacteriophages [26].

Genetic material, such as antibiotic-resistance genes,can disseminate swiftly among bacteria of various species [15]. Heavy metals [24] and biofilm formation [25] contribute to the spread of antibiotic resistance.



FIGURE (7)Mechanism of antibiotic resistance spread among bacteria by conjugation and transformation.

5. Routes of Widespread Transmission

Antibiotic-resistant bacteria may disseminate via several routes, possibly leading to illnesses in varied environments. The precise processes of dissemination are contingent upon the bacterial species and the surrounding environment. Prevalent pathways comprise:

Person-to-Person Transmission: Resistant bacteria may be disseminated by direct contact, such as handshaking with an infected person or through respiratory droplets generated by coughing or sneezing,impurified Surfaces: Resistant bacteria may last on surfaces like doorknobs, countertops, and medical apparatus for prolonged durations.When humans come into contact with these surfaces and then touch their faces or mouths, microorganisms may infiltrate the body and induce illnesses [27].

Healthcare environments, such as hospitals and medical institutions,are prime locations for resistant bacteria owing to insufficient infection control measures, substandard hygiene standards,and close patient contact. Healthcare personnel may unintentionally transmit resistant germs between patients if appropriate hygiene standards are not adhered to [28]

Transmission from Animals to People: Resistant bacteria may be transmitted from animals to people by direct contact with diseased animals or via the consumption of contaminated meat or dairy products. Antibiotic use in agriculture, especially in animals, is a major contributor to this transmission [29].

International travel promotes the spread of resistant germs across borders. Infected or colonised persons may inadvertently transport and spread resistant strains to other areas, hindering worldwide efforts to combat antibiotic resistance [27].

The processes of bacterial transmission and dissemination might significantly differ based on the particular bacterial species and the environmental situation. Moreover, elements, including substandard hygiene, insufficient sanitation, and

deficient infection control measures, significantly contribute to the spread of resistant bacteria [30].

6. Determinants Influencing Antibiotic Resistance

Antibiotic resistance is considerably exacerbated by the inappropriate, insufficient, or excessive use of antibiotics[31].The indiscriminate use of antibiotics, a principal factor in resistance development, is influenced by multiple elements, such as patient noncompliance with prescribed regimens, irrational prescribing behaviors by healthcare professionals, deceptive pharmaceutical marketing, improper dispensing practices,agricultural antibiotic usage,substandard antibiotics,inadequate surveillance mechanisms,and insufficient susceptibility testing. Moreover, patient demand often affects prescribers, even when antibiotics are not clinically warranted, hence increasing resistance [32].

Patients sometimes cease their therapies upon symptom alleviation,neglect to adhere to specified dosages or acquire just a portion of their prescriptions. These behaviors underscore the need for improved physician-patient communication to guarantee compliance with treatment regimens [33]. The accessibility of over-the-counter antibiotics in some areas exacerbates overuse, allowing patients to self-medicate without enough supervision [34].

The pharmaceutical business significantly contributes to antibiotic overuse via aggressive marketing strategies. Certain advertising has portrayed antibiotics such as ciprofloxacin as the preferred option for high-risk individuals. Historically, marketing in the Philippines endorsed lincomycin for pharyngitis or tonsillitis and clindamycin for upper respiratory tract infections, even though both ailments are of viral origin and do not need antibiotics [35].Confronting these difficulties requires a cooperative strategy that includes healthcare professionals, patients, and the pharmaceutical sector.

Healthcare workers profoundly impact the development of antibiotic resistance. Broad-spectrum antibiotics are often used when narrow-spectrum alternatives would be more suitable[36].Research indicates that 30%–60% of patients are prescribed antibiotics needlessly,highlighting the necessity for improved prescription standards.Moreover, erroneous prescriptions and guidance from inadequately qualified medical practitioners present considerable hazards. Studies demonstrate that private practitioners often give superfluous antibiotics, hence exacerbating resistance [37].

Hospitals and clinics play a substantial role in the development of microbial resistance to antibiotics [25]. Inadequate infection control measures, including insufficient hand hygiene and infrequent glove changes, have been recognized as significant contributing factors [38]. The utilization of low-quality antibiotics presents a considerable challenge. This problem frequently stems from a lack of adherence to quality standards and inadequate monitoring systems, resulting in the distribution of expired or counterfeit antibiotics [39].

The inappropriate use of antibiotics in livestock exacerbates the issue. Antibiotics are frequently used in animal husbandry to promote growth and prevent disease [40] . Inadequate surveillance and susceptibility testing of antibiotics impede effective strategies to address resistance [41] (Table 2).

7. Alternative Strategies for Addressing Antibiotic Resistance

The global crisis of antibiotic resistance poses a significant and escalating threat to public health across the globe. Addressing this challenge requires a transition to innovative strategies to effectively manage and reduce the increasing resistance. This review examines various alternative strategies designed to address this significant issue, as detailed below:

8. Identification of Novel Antibiotics

Recent advancements indicate the potential of novel strategies in discovering new antibiotics. In 2015, researchers discovered teixobactin, an innovative antibiotic exhibiting bactericidal properties against S. aureus, Clostridium difficile, and Bacillus anthracis [42].

On February 20, 2020, an article titled "A Deep Learning Approach to Antibiotic Discovery" was published in the journal Cell by researchers. Through the application of artificial intelligence, researchers identified a new antibiotic, halicin, exhibiting bactericidal properties against a wide range of pathogenic and resistant bacteria [43].

On September 26, 2022, an article in Nature Microbiology titled "Computational Identification of a Systemic Antibiotic for Gram-negative Bacteria" reported the discovery of dynactin. This antibiotic, discovered via computational screening, demonstrated significant bactericidal efficacy against Gram-negative bacteria resistant to alternative antibiotics [44].

9. Challenges in the Antibiotic R&D Market

The landscape of research and development for antibiotics encounters various challenges and limitations. Economic, regulatory, and scientific barriers impede the discovery and development of effective antibiotics for bacterial infections. The primary challenges in this ineffective R&D market are:

9.1 Scientific Challenges

Antibiotic Resistance: The increasing occurrence of antibiotic-resistant bacteria presents a significant obstacle to the creation of effective new antibiotics [45].

Limited Understanding of Bacterial Biology: Despite advancements in genomics and related technologies, there are substantial gaps in the understanding of bacterial biology and resistance mechanisms, hindering the development of targeted treatments [45].

9.2 Economic Challenges

Restricted Financial Motivations: The substantial expenses and limited profitability linked to the development of new antibiotics have dissuaded considerable investment from pharmaceutical firms [46].

Long Development Timelines: The protracted and expensive nature of antibiotic development renders it a less appealing sector for investment [47].

9.3 Regulatory Challenges

Strict Regulatory Standards: The process for approving new antibiotics is complex and time-consuming, leading to delays in the market introduction of new drugs [45].

Insufficient Direction on Clinical Trial Design: The absence of clearly established guidelines for antibiotic-specific clinical trial designs impedes the development process [45].

9.4 Adjuvants for Antibiotics

Antibiotic adjuvants are compounds that enhance the efficacy of antibiotics by targeting and inhibiting bacterial resistance mechanisms despite not being directly bactericidal. ß-lactamase inhibitors serve as small-molecule adjuvants. Inhibitors, when used in conjunction with ß-lactam antibiotics, have demonstrated efficacy for over 30 years in the treatment of various Gram-positive and Gram-negative bacterial infections. Their efficacy and broad utilization have been thoroughly documented in the literature [48].

9.5 Botanicals

Plants produce various secondary metabolites, such as alkaloids, flavonoids, phenolics, quinones, tannins, coumarins, terpenes, lectins, and saponins. These compounds exhibit antimicrobial activity against various microorganisms, suggesting their potential as alternative therapeutic agents [49].

9.6 Nano Antibiotics

Nano antibiotics, which consist of either pure antibiotic molecules sized between 1 and 100 nm or antibiotics physically bound to nanoparticles, exemplify a novel application of nanotechnology[50]. This innovative approach reengineers antibiotics at the nanoscale, significantly enhancing the efficacy of existing drugs against various clinically important microorganisms. Unlike bulk chemical antibiotics, nano antibiotics demonstrate distinct physicochemical properties and enhanced antimicrobial efficacy [51].

Nanoscale drug delivery systems offer distinct advantages through their ability to target and bind specifically to intracellular bacterial structures. This targeted delivery inhibits bacterial growth and metabolism, leading to cell death. Consequently, antibiotics administered via nanoparticles demonstrate significantly enhanced inhibitory effects on bacterial growth at comparable doses relative to traditional formulations [52].

CONCLUSION

This review article has analyzed several aspects of antibiotics, their mechanisms of action, the problem of antibiotic resistance, and potential techniques to combat resistance. Antibiotics have many applications across several fields, yet their usage is problematic owing to issues of resistance. Antibiotics operate via four primary mechanisms to eliminate or inhibit bacterial proliferation. Nevertheless, bacteria have developed strategies to resist antibiotics, hence reducing the efficacy of these medications. Given the limited effectiveness of traditional antibiotics due to resistance, we explored many alternative tactics, including the discovery of new antibiotics, the use of antibiotic adjuvants and nanoparticle-based antibiotics, phytotherapeutics, and bacteriophages. Despite the challenges in developing new antibiotics, a synergistic

strategy, including nanoantibiotics, adjuvants, botanicals, and phage therapy, may successfully address the issue of resistance.

REFERENCES

1. World Health Organization (WHO). Priority Medicines for Europe and the World/Warren Kaplan, Richard Laing 2004. Available online: https://iris.who.int/handle/10665/68769?show=full (accessed on 25 August 2023).
2. Rehman, M.T.; Faheem, M.; Khan, A.U. An insight into the biophysical characterization of different states of cefotaxime hydrolyzing _-lactamase 15 (CTX-M-15). J. Biomol. Struct. Dyn. **2015**, 33, 625–638. [CrossRef] [PubMed]
3. Livermore, D.M. Bacterial Resistance: Origins, Epidemiology, and Impact. Clin. Infect. Dis. **2003**, 36, S11–S23. [CrossRef]
[PubMed]
4. Muteeb, G.; Alsultan, A.; Farhan, M.; Aatif, M. Risedronate and Methotrexate Are High-Affinity Inhibitors of New Delhi Metallo-_-Lactamase-1 (NDM-1): A Drug Repurposing Approach. Molecules **2022**, 27, 1283. [CrossRef]
5. Khan, A.U.; Rehman, M.T. Role of Non-Active-Site Residue Trp-93 in the Function and Stability of New Delhi Metallo-_-Lactamase 1. Antimicrob. Agents Chemother. **2016**, 60, 356–360. [CrossRef] [PubMed]
6. Gould, K. Antibiotics: From prehistory to the present day. J. Antimicrob. Chemother. **2016**, 71, 572–575. [CrossRef]
7. Clardy, J.; Fischbach, M.A.; Currie, C.R. The natural history of antibiotics. Curr. Biol. **2009**, 19, R437–R441. [CrossRef]
8. Fleming, A. On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to their Use in the Isolation of B. influenzæ. Br. J. Exp. Pathol. **1929**, 10, 226–236. [CrossRef]
9. Hodgkin, D.C. The X-ray analysis of the structure of penicillin. Adv. Sci. **1949**, 6, 85–89.
10. Sheehan, J.C.; Henery-Logan, K.R. The Total Synthesis of Penicillin, V.J. Am. Chem. Soc. **1959**, 81, 3089–3094. [CrossRef]
11. Von Döhren, H. Antibiotics: Actions, Origins, Resistance, by C. Walsh. 2003; ASM Press: Washington, DC, USA, 2009; Volume 13, p. 345.
12. Abraham, E.P.; Chain, E. An Enzyme from Bacteria able to Destroy Penicillin. Nature **1940**, 146, 837. [CrossRef]
13. Aminov, R.I. A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future. Front. Microbiol. **2010**, 1, 134. [CrossRef] [PubMed]
14. Durand, G.A.; Raoult, D.; Dubourg, G. Antibiotic discovery: History, methods and perspectives. Int. J. Antimicrob. Agents **2019**,53, 371–382. [CrossRef] [PubMed]
15. Iskandar, K.; Murugaiyan, J.; Hammoudi Halat, D.; Hage, S.E.; Chibabhai, V.; Adukkadukkam, S.; Roques, C.; Molinier, L.; Salameh, P.; Van Dongen, M. Antibiotic Discovery and Resistance: The Chase and the Race. Antibiotics **2022**, 11, 182. [CrossRef][PubMed]
16. Christensen, S.B. Drugs That Changed Society: History and Current Status of the Early Antibiotics: Salvarsan, Sulfonamides, and _-Lactams. Molecules **2021**, 26, 6057. [CrossRef]
17. Chait, R.; Vetsigian, K.; Kishony, R. What counters antibiotic resistance in nature? Nat. Chem. Biol. **2012**, 8, 2–5. [CrossRef] Pharmaceuticals **2023**, 16, 1615 45 of 54
18. Blair, J.M.A.;Webber, M.A.; Baylay, A.J.; Ogbolu, D.O.; Piddock, L.J.V. Molecular mechanisms of antibiotic resistance. Nat. Rev.Microbiol. **2015**, 13, 42–51. [CrossRef] [PubMed]
19. Livermore, D.M.; Blaser, M.; Carrs, O.; Cassell, G.; Fishman, N.; Guidos, R.; Levy, S.; Powers, J.; Norrby, R.; Tillotson, G.; et al.Discovery research: The scientific challenge of finding new antibiotics. J. Antimicrob. Chemother. **2011**, 66, 1941–1944. [CrossRef]
20. Saga, T.; Yamaguchi, K. History of antimicrobial agents and resistant bacteria. Japan Med. Assoc. J. **2009**, 52, 103–108.
21. Hwang, I.Y.; Tan, M.H.; Koh, E.; Ho, C.L.; Poh, C.L.; Chang, M.W. Reprogramming Microbes to Be Pathogen-Seeking Killers. ACS Synth. Biol. **2014**, 3, 228–237. [CrossRef]
22. Orfali, R.; Perveen, S.; AlAjmI, M.F.; Ghaffar, S.; Rehman, M.T.; AlanzI, A.R.; Gamea, S.B.; Essa Khwayri, M. Antimicrobial Activity of Dihydroisocoumarin Isolated from Wadi Lajab Sediment-Derived Fungus Penicillium chrysogenum: In Vitro and InSilico Study. Molecules **2022**, 27, 3630. [CrossRef] [PubMed]
23. Davies, J.; Davies, D. Origins and Evolution of Antibiotic Resistance. Microbiol. Mol. Biol. Rev. **2010**, 74, 417–433. [CrossRef]
24. Bartlett, J.G.; Gilbert, D.N.; Spellberg, B. SevenWays to Preserve the Miracle of Antibiotics. Clin. Infect. Dis. **2013**, 56, 1445–1450. [CrossRef] [PubMed]
25. Velez, R.; Sloand, E. Combating antibiotic resistance, mitigating future threats and ongoing initiatives. J. Clin. Nurs. **2016**, 25, 1886–1889. [CrossRef] [PubMed]
26. D'Costa, V.M.; McGrann, K.M.; Hughes, D.W.; Wright, G.D. Sampling the Antibiotic Resistome. Science **2006**, 311, 374–377.[CrossRef] [PubMed]
27. Peterson, E.; Kaur, P. Antibiotic Resistance Mechanisms in Bacteria: Relationships Between Resistance Determinants of Antibiotic Producers, Environmental Bacteria, and Clinical Pathogens. Front. Microbiol. **2018**, 9, 2928. [CrossRef]

28. Vega, N.M.; Gore, J. Collective antibiotic resistance: Mechanisms and implications. Curr. Opin. Microbiol. **2014**, 21, 28–34. [CrossRef] [PubMed]
29. Darby, E.M.; Trampari, E.; Siasat, P.; Gaya, M.S.; Alav, I.;Webber, M.A.; Blair, J.M.A. Molecular mechanisms of antibiotic resistance revisited. Nat. Rev. Microbiol. **2023**, 21, 280–295. [CrossRef]
30. Chellat, M.F.; Raguž, L.; Riedl, R. Targeting Antibiotic Resistance. Angew. Chemie Int. Ed. **2016**, 55, 6600–6626. [CrossRef]
31. Akova, M. Epidemiology of antimicrobial resistance in bloodstream infections. Virulence **2016**, 7, 252–266. [CrossRef]
32. Martínez, J.L.; Rojo, F. Metabolic regulation of antibiotic resistance. FEMS Microbiol. Rev. **2011**, 35, 768–789. [CrossRef]
33. Akiba, M.; Sekizuka, T.; Yamashita, A.; Kuroda, M.; Fujii, Y.; Murata, M.; Lee, K.-I.; Joshua, D.I.; Balakrishna, K.; Bairy, I.; et al. Distribution and Relationships of Antimicrobial Resistance Determinants among Extended Spectrum-Cephalosporin-Resistant or Carbapenem-Resistant Escherichia coli Isolates from Rivers and Sewage Treatment Plants in India. Antimicrob. Agents Chemother.**2016**, 60, 2972–2980. [CrossRef]
34. Heddle, J.; Maxwell, A. Quinolone-Binding Pocket of DNA Gyrase: Role of GyrB. Antimicrob. Agents Chemother. **2002**, 46,1805–1815. [CrossRef] [PubMed]
35. Romano, M.; Iovene, M.R.; Russo, M.I.; Rocco, A.; Salerno, R.; Cozzolino, D.; Pilloni, A.P.; Tufano, M.A.; Vaira, D.; Nardone, G. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinicalisolates. J. Clin. Pathol. **2008**, 61, 1112–1115. [CrossRef]
36. Vester, B.; Douthwaite, S. Macrolide Resistance Conferred by Base Substitutions in 23S rRNA. Antimicrob. Agents Chemother. **2001**,45, 1–12. [CrossRef]
37. Hopwood, D.A. How do antibiotic-producing bacteria ensure their self-resistance before antibiotic biosynthesis incapacitatesthem? Mol. Microbiol. **2007**, 63, 937–940. [CrossRef]
38. Tahlan, K.; Ahn, S.K.; Sing, A.; Bodnaruk, T.D.; Willems, A.R.; Davidson, A.R.; Nodwell, J.R. Initiation of actinorhodin export inStreptomyces coelicolor. Mol. Microbiol. **2007**, 63, 951–961. [CrossRef] [PubMed]
39. Wright, G.D. Q&A: Antibiotic resistance: Where does it come from and what can we do about it? BMC Biol. **2010**, 8, 6.40. Allen, H.K.; Donato, J.; Wang, H.H.; Cloud-Hansen, K.A.; Davies, J.; Handelsman, J. Call of the wild: Antibiotic resistance genesin natural environments. Nat. Rev. Microbiol. **2010**, 8, 251–259. [CrossRef] [PubMed]
41. Wilson, D.N.; Hauryliuk, V.; Atkinson, G.C.; O'Neill, A.J. Target protection as a key antibiotic resistance mechanism. Nat. Rev.Microbiol. **2020**, 18, 637–648. [CrossRef]
42. Kapur, V.; Li, L.L.; Iordanescu, S.; Hamrick, M.R.; Wanger, A.; Kreiswirth, B.N.; Musser, J.M. Characterization by automated DNAsequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacteriumtuberculosis strains from New York City and Texas. J. Clin. Microbiol. **1994**, 32, 1095–1098. [CrossRef] [PubMed]
43. Wichelhaus, T.A.; Schafer, V.; Brade, V.; Boddinghaus, B. Molecular Characterization of rpoB Mutations Conferring Cross-Resistance to Rifamycins on Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. **1999**, 43, 2813–2816.[CrossRef]
44. Adam, M.; Murali, B.; Glenn, N.O.; Potter, S.S. Epigenetic inheritance based evolution of antibiotic resistance in bacteria. BMC Evol. Biol. **2008**, 8, 52.
[CrossRef]
45. AlAjmi, M.F.; Rehman, M.T.; Hussain, A.; Rather, G.M. Pharmacoinformatics approach for the identification of Polo-like kinase-1inhibitors from natural sources as anti-cancer agents. Int. J. Biol. Macromol. **2018**, 116, 173–181. [CrossRef]
46. Forsberg, K.J.; Reyes, A.;Wang, B.; Selleck, E.M.; Sommer, M.O.A.; Dantas, G. The Shared Antibiotic Resistome of Soil Bacteria and Human Pathogens. Science **2012**, 337, 1107–1111. [CrossRef] Pharmaceuticals **2023**, 16, 1615 46 of 54
47. Colomer-Lluch, M.; Jofre, J.; Muniesa, M. Antibiotic Resistance Genes in the Bacteriophage DNA Fraction of Environmental Samples. PLoS ONE **2011**, 6, e17549. [CrossRef]
48. Lerminiaux, N.A.; Cameron, A.D.S. Horizontal transfer of antibiotic resistance genes in clinical environments. Can. J. Microbiol.**2019**, 65, 34–44. [CrossRef]
49. Baker, K.S.; Dallman, T.J.; Field, N.; Childs, T.; Mitchell, H.; Day, M.; Weill, F.-X.; Lefèvre, S.; Tourdjman, M.; Hughes, G.; et al. Horizontal antimicrobial resistance transfer drives epidemics of multiple Shigella species. Nat. Commun. **2018**, 9, 1462. [CrossRef]
50. Paterson, D.L.; Bonomo, R.A. Extended-Spectrum _-Lactamases: A Clinical Update. Clin. Microbiol. Rev. **2005**, 18, 657–686.[CrossRef]
51. Mathers, A.J.; Cox, H.L.; Kitchel, B.; Bonatti, H.; Brassinga, A.K.C.; Carroll, J.; Scheld,W.M.; Hazen, K.C.; Sifri, C.D. MolecularDissection of an Outbreak of Carbapenem-Resistant Enterobacteriaceae Reveals Intergenus KPCCarbapenemase Transmissionthrough a Promiscuous Plasmid. mBio **2011**, 2, 10–1128. [CrossRef]
52. Balm, M.N.D.; Ngan, G.; Jureen, R.; Lin, R.T.P.; Teo, J.W.P. OXA-181-producing Klebsiella pneumoniae establishing in Singapore.BMC Infect. Dis. **2013**, 13, 58. [CrossRef]
53. Huang, T.-W.; Lauderdale, T.-L.; Liao, T.-L.; Hsu, M.-C.; Chang, F.-Y.; Chang, S.-C.; Khong, W.X.; Ng, O.T.; Chen, Y.-T.; Kuo, S.-C.;et al. Effective transfer of a 47 kb NDM-1-positive plasmid among Acinetobacter species. J. Antimicrob. Chemother. **2015**, 70,2734–2738. [CrossRef]
54. Martin, J.; Phan, H.T.T.; Findlay, J.; Stoesser, N.; Pankhurst, L.; Navickaite, I.; De Maio, N.; Eyre, D.W.; Toogood, G.; Orsi,N.M.; et al. Covert dissemination of carbapenemase-producing Klebsiella pneumoniae (KPC) in

successfully controlled outbreak: Long- and short-read whole-genome sequencing demonstrate multiple genetic modes of transmission. J. Antimicrob. Chemother. **2017**, 72, 3025–3034. [CrossRef]
55. Gorrie, C.L.; Mirceta, M.;Wick, R.R.; Judd, L.M.;Wyres, K.L.; Thomson, N.R.; Strugnell, R.A.; Pratt, N.F.; Garlick, J.S.;Watson, K.M.; et al. Antimicrobial-Resistant Klebsiella pneumoniae Carriage and Infection in Specialized Geriatric Care Wards Linked to Acquisition in the Referring Hospital. Clin. Infect. Dis. **2018**, 67, 161–170. [CrossRef]
56. Virolle, C.; Goldlust, K.; Djermoun, S.; Bigot, S.; Lesterlin, C. Plasmid Transfer by Conjugation in Gram-Negative Bacteria: From the Cellular to the Community Level. Genes **2020**, 11, 1239. [CrossRef] [PubMed]
57. Stanczak-Mrozek, K.I.; Manne, A.; Knight, G.M.; Gould, K.; Witney, A.A.; Lindsay, J.A. Within-host diversity of MRSA antimicrobial resistances. J. Antimicrob. Chemother. **2015**, 70, 2191–2198. [CrossRef] [PubMed]
58. Mašlaˇnová, I.; Stˇríbná, S.; Doškaˇr, J.; Pant °uˇcek, R. Efficient plasmid transduction to Staphylococcus aureus strains insensitive to the lytic action of transducing phage. FEMS Microbiol. Lett. **2016**, 363, fnw211. [CrossRef] [PubMed]
59. Blahová, J.; Králiková, K.; Krˇcméry, V.; Ježek, P. Low-Frequency Transduction of Imipenem Resistance and High-FrequencyTransduction of Ceftazidime and Aztreonam Resistance by the Bacteriophage AP-151 Isolated from a Pseudomonas aeruginosa Strain. J. Chemother. **2000**, 12, 482–486. [CrossRef]
60. Krahn, T.;Wibberg, D.; Maus, I.;Winkler, A.; Bontron, S.; Sczyrba, A.; Nordmann, P.; Pühler, A.; Poirel, L.; Schlüter, A. Intraspecies Transfer of the Chromosomal Acinetobacter baumannii bla NDM-1 Carbapenemase Gene. Antimicrob. Agents Chemother. **2016**, 60,
3032–3040. [CrossRef]
61. Zeman, M.; Mašlaˇnová, I.; Indráková, A.; Šiborová, M.; Mikulášek, K.; Bendíˇcková, K.; Plevka, P.; Vrbovská, V.; Zdráhal, Z.; Doškaˇr, J.; et al. Staphylococcus sciuri bacteriophages double-convert for staphylokinase and phospholipase, mediate interspecies plasmid transduction, and package mecA gene. Sci. Rep. **2017**, 7, 46319. [CrossRef] [PubMed]
62. Oliver, A.; Coque, T.M.; Alonso, D.; Valverde, A.; Baquero, F.; Cantón, R. CTX-M-10 Linked to a Phage-Related Element Is Widely Disseminated among Enterobacteriaceae in a Spanish Hospital. Antimicrob. Agents Chemother. **2005**, 49, 1567–1571. [CrossRef][PubMed]
63. Traglia, G.M.; Chua, K.; Centrón, D.; Tolmasky, M.E.; Ramírez, M.S. Whole-Genome Sequence Analysis of the NaturallyCompetent Acinetobacter baumannii Clinical Isolate A118. Genome Biol. Evol. **2014**, 6, 2235–2239. [CrossRef] [PubMed]